Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zambon Launches Intravenous Formulation of Fluimucil
Details : Fluimucil (N-acetylcysteine) is a free radical inhibitor small molecule drug candidate, which is approved in china for the treatment of respiratory diseases.
Product Name : Fluimucil
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2025
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zambon Publishes Phase 3 PROMIS Results on CMS I-neb for NCFB Patients
Details : Colistimethate sodium cell membrane inhibitor, antibiotic drug, which is currently being evaluated for the treatment of non-cystic fibrosis bronchiectasis chronically infected with P. aeruginosa.
Product Name : CMS
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 13, 2024
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbidopa,Etilevodopa
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Details : Through the licensing agreement, Zambon will commercialize IPX203, an oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson’s disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 27, 2024
Lead Product(s) : Carbidopa,Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia
Details : Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2023
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Pari
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTO...
Product Name : L-CsA
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Pari
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
Details : Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease...
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KABP022,KABP023,KABP033
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Ab-Biotics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
February 21, 2022
Lead Product(s) : KABP022,KABP023,KABP033
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Ab-Biotics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, the company grants Zambon exclusive rights to commercialize Rivalif (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Product Name : Rivalif
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2021
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Agreement